Artios Pharma is a company focused on developing novel cancer treatments targeting the DNA Damage Response #DDR

Consulting

Artios Pharma

Artios Pharma's headquarters in Cambridge, MA, United States

Ian Smith

Colleen Murrett Sadin

Pri Pinnaduwa

Devon McArthur

Graeme Smith

Christine Silverstein

Sara Busacca

Robert Heald

Suraj Menon

Helen Robinson

John Graham

Bethany Mason

Desiree Headley

Bryony Harrop

Gillian Langford

Emma Stewart

Bonni Roark

Jamie Datol

Naseem Amin Md

Raj Chopra

Andrew Tutt

Geoff Higgins

Barbara Dalton

Jonathan Ledermann

Adam Houghton

Peter Harris

Johann De Bono

Stephen V. Frye

Kevin Harrington

Lisa Patel

Harry Finch

René Kuijten

Geoff Shapiro

Raphael Wisniewski

Chen Yu

Michelle Doig

Nora Brennan

Samantha Truex

Mark Chin

Hakan Goker

Chris Lord

Pierre Legault

Nikola Trbovic

The Scientific Research and Development team at Artios Pharma is dedicated to advancing innovative cancer therapies by exploring the intricacies of the DNA Damage Response (DDR). This multidisciplinary team, comprising experts in biochemistry, medicinal chemistry, and translational science, collaborates to identify and validate novel drug targets, optimize therapeutic candidates, and conduct rigorous preclinical studies. Their efforts aim to translate groundbreaking scientific discoveries into effective treatments for cancer patients.

Scientific Research and Development

The Clinical Development Team at Artios Pharma is responsible for designing and overseeing clinical trials aimed at evaluating the safety and efficacy of novel cancer treatments that target the DNA Damage Response (DDR). Comprised of clinical advisors, consultants, trial managers, and scientists, the team collaborates to ensure the successful execution of clinical protocols, seeks regulatory approvals, and analyzes trial data to advance innovative therapies that improve patient outcomes.

Clinical Development Team

This department provides strategic direction and oversight for the organization.

Leadership

The Leadership Team at Artios Pharma is responsible for setting the strategic direction and overseeing the execution of initiatives aimed at advancing the development of innovative cancer therapies targeting the DNA Damage Response. Comprised of key executives including the CEO, Chief Scientific Officer, and Chief Medical Officer, the team collaborates to align scientific, operational, and clinical efforts, ensuring the company's goals are met while fostering a culture of collaboration and excellence.

Leadership Team

The Research and Scientific Development team at Artios Pharma is dedicated to advancing innovative cancer therapies by focusing on the DNA Damage Response (DDR). This multidisciplinary team collaborates on early research, preclinical studies, and the translation of scientific insights into actionable treatment strategies, leveraging expertise in biology, bioinformatics, pharmacology, and analytical chemistry to drive the next generation of cancer treatments.

Research and Scientific Development

The Clinical Operations team at Artios Pharma is responsible for overseeing the planning, execution, and management of clinical trials for innovative cancer therapies. This includes coordinating logistics, ensuring compliance with regulatory standards, and managing trial supplies to support effective investigation of DNA Damage Response targets. The team collaborates closely with cross-functional partners to drive research forward while prioritizing patient safety and data integrity.

Clinical Operations

��

Artios Pharma

Org chart

Board & advisors

Teams

Scientific Research and Development

Clinical Development Team

Leadership

Leadership Team

Research and Scientific Development

Clinical Operations

Offices

��������

Artios Pharma

Org chart

Board & advisors

Teams

Scientific Research and Development

Clinical Development Team

Leadership

Leadership Team

Research and Scientific Development

Clinical Operations

Offices

Related companies

��